Healthcare (Substance Abuse)

This bill requires Medicaid plans and health carriers to treat nonopioid pain medications approved by the FDA equally with opioid drugs in coverage decisions. Specifically, nonopioid drugs cannot be labeled as "nonpreferred" if opioids are preferred, and must face no stricter coverage requirements (like prior authorization) than opioids. Health carriers must also create and submit "pain management access plans" covering at least two non-opioid prescription medications and three non-drug pain treatments (e.g., physical therapy), ensuring these options aren’t blocked by excessive barriers. The rules apply immediately upon FDA approval of a nonopioid drug, bypassing standard committee review for inclusion on preferred drug lists. This directly affects Medicaid managed care organizations and health insurance providers in Iowa.

This bill requires Medicaid and health insurers to treat nonopioid pain medications equally with opioids in coverage. It prohibits designating nonopioid drugs as "nonpreferred" when opioids are preferred and bans stricter prior authorization or step therapy requirements for nonopioid drugs compared to opioids. Health insurers must develop a "pain management access plan" covering at least two FDA-approved non-opioid prescription medications (not controlled substances) and three non-drug pain treatments, without more restrictive rules for nonopioid options. The bill applies immediately upon FDA approval of a nonopioid pain drug, regardless of prior committee review. It affects Medicaid managed care organizations and health carriers offering coverage in Iowa.

This bill allows physician assistants and advanced registered nurse practitioners (ARNPs) to testify at Iowa's involuntary commitment hearings on behalf of licensed physicians or mental health professionals who examined the respondent. To qualify, the PA/ARNP must provide three sworn statements: confirming they witnessed the exam, reviewed the written report, and that the primary provider cannot attend. It applies to both mental health and substance abuse commitment hearings, directly affecting respondents, their attorneys, and healthcare providers involved in these proceedings. The change streamlines testimony options while maintaining court oversight for waiver decisions.

SF 264 creates a Prescription Drug Affordability Board in Iowa to address high prescription drug costs. The board, appointed by the governor with Senate confirmation, will review drug pricing and may recommend upper payment limits for prescription drugs affecting all Iowans, especially patients with illnesses, opioid crisis communities, and healthcare providers. Key provisions require the board to hold public meetings, accept public input, and enforce strict conflict-of-interest rules (e.g., members cannot receive over $5,000 annually from drug manufacturers). The bill establishes this mechanism to review drug costs but does not yet implement price controls.